anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Vilazodone
Trial phase: Not Applicable
ATC code: N06AX24
SMILES: N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks

vilazodone: capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
Eligibility criteria:
Inclusion Criteria:

Women ages 45-60 years
Amenorrhea for 60 days or more or postmenopausal or bi-lateral oophorectomy.
4 or more moderate or severe hot flashes or night sweats per 24 hour period (28/week) as recorded on daily diaries in 3 screening weeks.
Hot flashes/night sweats rated as moderate to severe and/or bothersome (moderately to a lot) on 4 or more days/nights in each screen week.
In general good health.
Signed informed consent.

Exclusion Criteria:

Psychotropic medications currently or within the last 30 days.
Current use of hormonal medications such as hormone therapy or hormonal contraception or any treatment for hot flashes (Prescription, over-the-counter or herbal).
Drug or alcohol abuse in the past year.
Lifetime diagnosis of psychosis or bipolar disorder.
Suicide attempt in the past 3 years or any current suicidal ideation.
Current major depression.
Not using a medically approved, non-hormonal method of birth control if sexually active and not postmenopausal (12 or more months since last menstrual period or bi-lateral oophorectomy).
Pregnancy, intending pregnancy or breast feeding.
Any severe of unstable medical illness, e.g., breast or ovarian cancer, seizure disorders, etc.
Current participation in another intervention study.
Inability or unwillingness to complete study procedures.
Intervention: Gibberellin A101
Trial phase: Phase 1
SMILES: C=C1C(O)C23CC1(O)CCC2C12CCCC(C)(C(=O)OC1)C2C3C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Participants with DLBCL received 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab were administered on Cycle 1 Day 8 and Day 15.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of CD20+ B-cell lymphoma or B-CLL
Refractory/relapsed CLL, FL, and DLBCL
At least 1 measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension) with the exception of CLL
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy >6 months

Exclusion Criteria:

Prior use of any investigational antibody therapy within 6 months of study start
Prior use of any anti-cancer vaccine
Prior administration of rituximab within 3 months of study start
Prior administration of radioimmunotherapy 3 months prior to study entry
Central nervous system lymphoma
History of other malignancy
Evidence of significant, uncontrolled concomitant disease
Abnormal laboratory values
Patients with progressive multifocalleukoencephalopathy (PML)
Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Intervention: Solriamfetol
Trial phase: Phase 2
ATC code: N06BA14
SMILES: NC(=O)OC[C@H](N)Cc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: ADX-N05 to be taken once a day for 12 weeks

ADX-N05: 150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
Eligibility criteria:
Inclusion Criteria:

Diagnosis of narcolepsy
Good general health
Willing and able to comply with the study design and schedule and other requirements

Exclusion Criteria:

If female, pregnant or lactating
Customary bedtime later than midnight
History of significant medical condition, behavioral, or psychiatric disorder (including suicidal ideation), or surgical history
Any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
History of significant cardiovascular disease
Body mass index > 34
Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day
History of alcohol or drug abuse within the past 2 years
Nicotine dependence that has an effect on sleep
Intervention: Nitisinone
Trial phase: Phase 1
ATC code: A16AX04
SMILES: O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Orfadin capsules, single dose, 30 mg
Eligibility criteria:
Inclusion Criteria:

Healthy male volunteers
Age: 18-55 years, inclusive
BMI: 18,5-30,0 kg/m2, inclusive

Exclusion Criteria:

heavy smokers
Consumption of more than 4 cups of coffee per day.
History of drug and/or alcohol abuse.
Positive drug screen or alcohol breath test.
Positive screens for hepatitis B surface antigen, hepatitis C antibodies and human immunodeficiency virus (HIV) 1-2 antibodies.
Enrollment in another concurrent clinical study
Intake of an investigational medicinal product within three months prior to inclusion in this study.
Donation of more than 50 mL of blood within 60 days prior to drug administration
Donation of more than 1,5 liters of blood in the 10 months prior to first drug administration.
Intervention: Nitisinone
Trial phase: Phase 1
ATC code: A16AX04
SMILES: O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Orfadin suspension 4 mg/mL, single dose, 30 mg (7.5 mL)
Eligibility criteria:
Inclusion Criteria:

Healthy male volunteers
Age: 18-55 years, inclusive
BMI: 18,5-30,0 kg/m2, inclusive

Exclusion Criteria:

heavy smokers
Consumption of more than 4 cups of coffee per day.
History of drug and/or alcohol abuse.
Positive drug screen or alcohol breath test.
Positive screens for hepatitis B surface antigen, hepatitis C antibodies and human immunodeficiency virus (HIV) 1-2 antibodies.
Enrollment in another concurrent clinical study
Intake of an investigational medicinal product within three months prior to inclusion in this study.
Donation of more than 50 mL of blood within 60 days prior to drug administration
Donation of more than 1,5 liters of blood in the 10 months prior to first drug administration.
Intervention: Basaglar
Trial phase: Phase 3
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 275
Group description: Lantus SC injection once daily in morning or evening for 12 months on top of mealtime insulin.
Eligibility criteria:
Inclusion criteria:

Adult participants with type 1 diabetes mellitus

Exclusion criteria:

HbA1c less than (<) 7.0% (53 mmol/mol) or greater than (>) 10% (86 mmol/mol) at screening
Less than 1 year on any basal plus mealtime insulin and self-monitoring of blood glucose before screening visit
Participants not on stable insulin dose (+/-20 percent total basal insulin dose) in the last 30 days prior to screening visit
Participants using pre-mix insulins, human regular insulin as mealtime insulin and/or any glucose-lowering drugs other than basal insulin and mealtime analogue insulin in the last 3 months before screening visit
Use of an insulin pump in the last 6 months before screening visit and no plan to switch to insulin pump in the next 12 months
Not willing to inject insulin glargine as assigned by the randomization process once daily in the morning or evening;
Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit
Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (example laser, surgical treatment or injectable drugs) during the study period

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Intervention: Rivaroxaban
Trial phase: Phase 2
ATC code: B01AF01
SMILES: O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 13
Group description: Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
Eligibility criteria:
Inclusion Criteria:

Children aged 6 to < 18 years with documented symptomatic or asymptomatic venous thrombosis treated for at least 2 months or, in case of catheter related thrombosis, treated for at least 6 weeks with LMWH (low molecular weight heparin), , fondaparinux and/or VKA (vitamin K antagonist).
Informed consent provided and, if applicable, child assent provided

Exclusion Criteria:

Active bleeding or high risk for bleeding contraindicating anticoagulant therapy
Symptomatic progression of venous thrombosis during preceding anticoagulant treatment
Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment
An estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2
Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk or ALT > 5x upper level of normal (ULN) or total bilirubin > 2x ULN with direct bilirubin > 20% of the total
Platelet count < 50 x 10^9/L
Hypertension defined as > 95th age percentile
Life expectancy < 3 months
Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e. all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically
Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
Intervention: Cetirizine
Trial phase: Phase 3
ATC code: R06AE07 | R06AE09 | S01GX12
SMILES: O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: AC-170 0.24%: 1 drop in each eye at 2 separate times during a 14 day period
Eligibility criteria:
Inclusion Criteria:

positive bilateral conjunctival allergen challenge (CAC)reaction

Exclusion Criteria:

known contraindications or sensitivities to the study medication or its components
any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
use of disallowed medication during the period indicated prior to the enrollment or during the study
Intervention: Cetirizine
Trial phase: Phase 3
ATC code: R06AE07 | R06AE09 | S01GX12
SMILES: O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: AC-170 0%: 1 drop in each eye at 2 separate times during a 14 day period
Eligibility criteria:
Inclusion Criteria:

positive bilateral conjunctival allergen challenge (CAC)reaction

Exclusion Criteria:

known contraindications or sensitivities to the study medication or its components
any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
use of disallowed medication during the period indicated prior to the enrollment or during the study
Intervention: Zonisamide
Trial phase: Phase 1 | Phase 2
ATC code: G01AE10 | N03AX15
SMILES: NS(=O)(=O)Cc1noc2ccccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: participants will receive zonisamide capsules (up to 300 mg) to take once a day.

zonisamide: In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
Eligibility criteria:
Inclusion Criteria:

Ages 18 - 65 years old; smoking > 10 cigarettes per day for > 1 year
Desire to quit smoking
Provide a cotinine positive urine sample
Commitment to come to the clinic once a week for the 10-week study duration

Exclusion Criteria:

Allergy to varenicline or sulfonamide drugs (e.g., trimethoprim/sulfamethoxazole, zonisamide or topiramate);
Renal insufficiency (eGFR < 60 mL)
Renal tubular acidosis
History of nephrolithiasis
Unexplained hematuria
Transaminase elevations > 3 times the Upper Limit of Normal (ULN)
BMI < 19
Diabetes mellitus
Respiratory insufficiency
Asthma requiring medication
Heart failure
Chronic diarrhea predisposing to acidosis
Glaucoma, family history of glaucoma, one-sided blindness
History of seizures or use of anticonvulsant medications (not including sedatives)
HIV infection on HAART medication (or CD4 T cell count < 200 /mL)
History of serious psychiatric disorder: psychosis, dementia, depression requiring medication in last 6 months, suicidal or homicidal ideation, evidence of violent behavior in the last 6 months.
Recent use (last 30 days) of bupropion, nortriptyline, or clonidine
Recent use (last 30 days) of Nicotine Replacement Products that would interfere with urine cotinine testing
Use of tobacco products other than cigarettes
For female participants, pregnancy, lactation, or refusal to use an effective method of contraception.
Intervention: Simvastatin
Trial phase: Phase 4
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Participants will receive 20mg of simvastatin daily for 4 weeks.

simvastatin : Participants will receive 20mg of simvastatin daily for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

LDL cholesterol level between 115-190 mg/dL;
Able to fast prior to blood draw;
Able to comfortably read and write in Chinese;
Able and willing to refrain from donating whole blood during study participation;
Willing to abstain from consuming large amounts of grapefruit juice.

Exclusion Criteria:

Current use of lipid-lowering medications;
Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);
Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria);
Patients with moderate to severe chronic kidney disease [glomerular filtration rate (GFR) < 60 mL/min/1.73㎡];
Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;
A calculated SCORE ≥5% for 10 year risk of fatal CVD;
Cancer;
HIV infected;
Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);
Active liver disease or unexplained persistent elevated transaminase levels；
Major surgery or hospitalization in the 3 months prior to study entry;
Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;
Female of childbearing potential;
Current participation in another clinical trial.
Intervention: Lovaza
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 31
Group description: Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
Eligibility criteria:
Inclusion criteria:

Age 18-65 years
Insulin resistant (Homeostasis Model Assessment (HOMA) Insulin Resistance (IR) ≥2.6)

Exclusion criteria:

Current use of omega-3 nutritional supplements
Fasting plasma glucose ≥126 mg/dL
Active coronary artery disease
Participation in structured exercise (>2 times per week for 30 minutes or longer)
Smoking
Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids, tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)
Renal failure (serum creatinine > 1.5mg/dl)
Chronic active liver disease (AST>144 IU/L and alanine transaminase (ALT)>165 IU/L)
Anti-coagulant therapy (warfarin/heparin)
International normalized ratio (INR) >3
Use of systemic glucocorticoids
Chronic use of NSAIDS or aspirin
Pregnancy or breastfeeding
Alcohol consumption greater than 2 glasses/day
Hypothyroidism
Fish or shellfish allergy
Intervention: Menthol
Trial phase: Not Applicable
SMILES: CC1CCC(C(C)C)C(O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects between the ages of 18 and 65, inclusive
Subjects diagnosed with episodic migraine, with or without aura according to IHS criteria for at least one year prior to screening
Subjects who experience between 1 and 10 migraine attacks (inclusive) per month (during the previous 6 months) with no more than 15 days of headache per month.
Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential
Subjects who are able to understand and comply with all study procedures.
Subject provides written informed consent prior to any screening procedures being conducted

Exclusion Criteria:

Pregnant and/or lactating women
Subjects who, in the investigator's opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
Subjects who currently have or have had a history of basilar or hemiplegic migraine
Intervention: Bupivacaine
Trial phase: Phase 1
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 135
Group description: The "Bupivacaine Arm" includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc.

Bupivacaine: Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
Eligibility criteria:
Inclusion Criteria:

Patients who are scheduled for a laparoscopic hysterectomy for benign indications at the Department of Obstetrics & Gynecology's Division of Minimally Invasive Surgery at Milton S. Hershey Medical Center will be included.

Exclusion Criteria:

Patients who are scheduled for a hysterectomy through the vaginal or abdominal approach will be excluded. Patients with preoperative indications of endometriosis or chronic pelvic pain will also be excluded since these patients could potentially have higher thresholds of pain.
Intervention: Hyaluronoglucosaminidase
Trial phase: Phase 2
SMILES: Br.C=C1N(CCCCCC(=O)O)c2ccccc2C1(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 253
Group description: Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two sites on their forearms
Eligibility criteria:
Inclusion Criteria:

Healthy volunteers of either gender; Those without clinically significant cardiovascular gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results, assessed according to the judgment of the Principal Investigator. A non-inclusive list which would not be exclusionary and define healthy individual for the purposes of this study are:

hypothyroidism,
stable hypertension except those subjects on beta blockers including ocular preparations,
seasonal/perennial allergic rhinitis if able to wash out of antihistamines,
stable, mild intermittent asthma (subjects using beta agonists as a monotherapy on an as-needed basis, excluding daily usage),
migraine if not taking excluded medications,
mild anxiety/depression if not taking excluded medications, and

mild arthritic conditions if not taking excluded medications.

Willingness and ability to sign an informed consent document;
18 - 80 years of age;
Intact skin at the forearm ;
Female participants are currently practicing effective birth control methods or abstinence.

Exclusion Criteria:

Known allergy, hypersensitivity or contraindications to hyaluronidase, thimerosal, edetate disodium (EDTA);
Use of medications within a duration considered to interfere with skin testing.
Known dermographism which may interfere with skin testing.
Pregnant or lactating women.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 253
Group description: Subjects received an intradermal injection of 0.02 mL saline at one site on their forearms
Eligibility criteria:
Inclusion Criteria:

Healthy volunteers of either gender; Those without clinically significant cardiovascular gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic disease that would unduly risk the subject's safety or interfere with the interpretation of results, assessed according to the judgment of the Principal Investigator. A non-inclusive list which would not be exclusionary and define healthy individual for the purposes of this study are:

hypothyroidism,
stable hypertension except those subjects on beta blockers including ocular preparations,
seasonal/perennial allergic rhinitis if able to wash out of antihistamines,
stable, mild intermittent asthma (subjects using beta agonists as a monotherapy on an as-needed basis, excluding daily usage),
migraine if not taking excluded medications,
mild anxiety/depression if not taking excluded medications, and

mild arthritic conditions if not taking excluded medications.

Willingness and ability to sign an informed consent document;
18 - 80 years of age;
Intact skin at the forearm ;
Female participants are currently practicing effective birth control methods or abstinence.

Exclusion Criteria:

Known allergy, hypersensitivity or contraindications to hyaluronidase, thimerosal, edetate disodium (EDTA);
Use of medications within a duration considered to interfere with skin testing.
Known dermographism which may interfere with skin testing.
Pregnant or lactating women.